Dianthus Therapeutics (NASDAQ:DNTH) CEO Marino Garcia Sells 166,000 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CEO Marino Garcia sold 166,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dianthus Therapeutics Stock Down 0.9%

DNTH stock opened at $108.92 on Friday. The stock has a 50-day simple moving average of $94.72 and a two-hundred day simple moving average of $80.65. Dianthus Therapeutics, Inc. has a twelve month low of $18.08 and a twelve month high of $114.55. The firm has a market capitalization of $5.95 billion, a PE ratio of -26.25 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its stake in shares of Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after buying an additional 139 shares during the last quarter. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at about $32,000. Virtus Investment Advisers LLC boosted its holdings in Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares during the period. Royal Bank of Canada boosted its holdings in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Analysts Set New Price Targets

DNTH has been the subject of several analyst reports. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday. Wedbush upped their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.